3. Relation of plasma kisspeptin-10 to altered reproductive hormones in preeclamptic pregnant women

• Published in: Pregnancy hypertension 2018-10, Vol.13, p.S51-S51
• Main Author: Farqad Hamdan, Hisham Al-Matubsi, Maysoun Al-Kaabi
• Format: Article
• Language: English
• ISSN: 2210-7789; 2210-7797
• DOI: 10.1016/j.preghy.2018.08.149

Hypertension and proteinuria associated with the diagnosis of preeclampsia (PE) following 20 weeks of gestation influences affects 5–10% of all pregnancies. More importantly, however, PE is the main cause of maternal and prenatal morbidity and mortality. To evaluate plasma kisspeptin-10 and assess its relation to altered reproductive hormones in preeclamptic pregnant women. First time pregnant women (N = 120) at 20 weeks of gestation participated in this study and divided into preeclamptics (N = 60) and normotensives (N = 60). The preeclamptics group were further subdivided into PE without severe features (N = 39) who were beforehand normotensive, or severe PE (N = 21). Kisspeptin-10, luteinizing hormone, follicle stimulating hormone, beta- human chorionic gonadotropin (β-HCG), estradiol, and progesterone were evaluated during second and third trimesters of pregnancy for all women. Kisspeptin-10 levels were reduced in severely preeclamptic women compared with uncomplicated pregnancies. During the second trimester, Kisspeptin-10 levels inversely correlated with severity of disease, whereas levels directly correlating with β- human chorionic gonadotropin, estradiol, and progesterone concentrations. Additionally, Kisspeptin-10 directly correlated with levels of follicle stimulating hormone during the third trimester in preeclamptic pregnant women. In contrast, Kisspeptin-10 inversely correlated with progesterone during the second trimester in preeclamptic patients without severe features, and during third trimester in patients with severe preeclampsia. Testing for maternal Kisspeptin-10 plasma levels may be useful as an effective screening tool to predict preeclampsia when used as a biomarker in association with another tests such as hormonal profiling.